1148157-30-5

Upstream product

• 501-53-1 benzyl chloroformate 

Downstream Products

• 1148157-32-7 C₂HF₃O₂*C₁₅H₂₂N₂O₅ 
• 935888-09-8 benzyl (2S)-2-[(2S)-2-{[tert-butoxycarbonyl]amino}-3-methoxypropanamido]-3-methoxypropanoate 

Relevant academic research and scientific papers

IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB

This disclosure features immediate release pharmaceutical formulations (e.g., solid dosage forms, e.g., tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the formulations.

GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOF

This disclosure features gastro-retentive (GR) modified release pharmaceutical dosage forms (e.g., solid dosage forms, e.g., tablets, e.g., bilayer tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the dosage form.

PROTEASOME INHIBITORS

The present invention relates to a compound of formula (I), wherein X is C=0, C=S or B-OH; Y is an electrophile and Z is a leaving group, or Y══Z is an electrophile; R1 comprises or consists of (a) (i) a first group binding to a proteolytic sit

Modified Release Formulations for Oprozomib

This disclosure features modified release pharmaceutical formulations (e.g., extended release pharmaceutical formulations; e.g., solid dosage forms, e.g., tablets) that are useful for the oral administration of oprozomib, or a pharmaceutically acceptable salt thereof, to a human or animal subject as well as methods of making and using the formulations.